CN116367843A - 病毒抑制剂 - Google Patents

病毒抑制剂 Download PDF

Info

Publication number
CN116367843A
CN116367843A CN202180066866.0A CN202180066866A CN116367843A CN 116367843 A CN116367843 A CN 116367843A CN 202180066866 A CN202180066866 A CN 202180066866A CN 116367843 A CN116367843 A CN 116367843A
Authority
CN
China
Prior art keywords
mol
substituted
amphiphilic
unsubstituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180066866.0A
Other languages
English (en)
Chinese (zh)
Inventor
I·乌切格布
A·沙茨林
K·彼拉斯
A·米卢斯卡
E·巴雷托杜兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanomerics Ltd
Original Assignee
Nanomerics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2013221.3A external-priority patent/GB202013221D0/en
Priority claimed from GBGB2019097.1A external-priority patent/GB202019097D0/en
Priority claimed from GBGB2105404.4A external-priority patent/GB202105404D0/en
Application filed by Nanomerics Ltd filed Critical Nanomerics Ltd
Publication of CN116367843A publication Critical patent/CN116367843A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180066866.0A 2020-08-24 2021-08-24 病毒抑制剂 Pending CN116367843A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2013221.3 2020-08-24
GBGB2013221.3A GB202013221D0 (en) 2020-08-24 2020-08-24 Viral inhibitors
GB2019097.1 2020-12-03
GBGB2019097.1A GB202019097D0 (en) 2020-12-03 2020-12-03 Viral inhibitors
GBGB2105404.4A GB202105404D0 (en) 2021-04-15 2021-04-15 Viral inhibitors
GB2105404.4 2021-04-15
PCT/GB2021/052199 WO2022043678A1 (en) 2020-08-24 2021-08-24 Viral inhibitors

Publications (1)

Publication Number Publication Date
CN116367843A true CN116367843A (zh) 2023-06-30

Family

ID=77655566

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180066866.0A Pending CN116367843A (zh) 2020-08-24 2021-08-24 病毒抑制剂

Country Status (8)

Country Link
US (1) US20230330132A1 (https=)
EP (1) EP4199937A1 (https=)
JP (1) JP2023538449A (https=)
CN (1) CN116367843A (https=)
AU (1) AU2021333748A1 (https=)
CA (1) CA3192515A1 (https=)
MX (1) MX2023002109A (https=)
WO (1) WO2022043678A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3194032A1 (en) * 2020-09-04 2022-03-10 The University Of Chicago Materials and methods of treating viral infection with amphiphilic block copolymers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279189A1 (en) * 2013-11-04 2016-09-29 Nanomerics Ltd Delivery of Drugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0221941D0 (en) * 2002-09-20 2002-10-30 Univ Strathclyde Polysoaps
CN100577179C (zh) * 2003-05-08 2010-01-06 天津帝士力投资控股集团有限公司 甲壳素和壳聚糖及其衍生物在制备抗病毒剂中的应用
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
GB0615834D0 (en) 2006-08-09 2006-09-20 Univ Glasgow Polymeric micellar clusters and their uses in formulating drugs
JP6028968B2 (ja) * 2012-02-24 2016-11-24 学校法人順天堂 抗インフルエンザウイルス剤
PL225045B1 (pl) * 2012-05-18 2017-02-28 Univ Jagiellonski Zastosowanie polimeru chitozanowego do wytwarzania leków do leczenia i profilaktyki infekcji wywołanych przez koronawirusy
WO2020039463A1 (en) * 2018-08-23 2020-02-27 Haskoli Islands Chitosan derivatives and methods for preparing the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279189A1 (en) * 2013-11-04 2016-09-29 Nanomerics Ltd Delivery of Drugs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KRZYSZTOF PYRĆ等: "SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray", 《BIORXIV》, 10 December 2020 (2020-12-10), pages 1 - 22 *
RAUL DIAZ-SALMERON等: "Hierarchically built hyaluronan nano-platelets have symmetrical hexagonal shape, flattened surfaces and controlled size", 《EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES》, vol. 133, 5 April 2019 (2019-04-05), pages 251 - 263, XP085666991, DOI: 10.1016/j.ejps.2019.04.007 *
UCHECHUKWU ODUNZE: "Engineering of Polymeric Nanoparticles Based on Structure-Activity Relationships (SARs) for Oral Drug Delivery", 《UCL DISCOVERY》, 31 July 2018 (2018-07-31), pages 1 - 292 *

Also Published As

Publication number Publication date
CA3192515A1 (en) 2022-03-03
MX2023002109A (es) 2023-07-13
WO2022043678A1 (en) 2022-03-03
EP4199937A1 (en) 2023-06-28
JP2023538449A (ja) 2023-09-07
US20230330132A1 (en) 2023-10-19
AU2021333748A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
AU2018201772A1 (en) Pharmaceutical nanoparticles showing improved mucosal transport
JP2010537997A (ja) 二機能性ポリマーに結合させたインフルエンザウイルス阻害剤
TW201121550A (en) Antisense antiviral compound and method for treating influenza viral infection
KR102007278B1 (ko) 바이러스 진단 및 치료를 위한 인지능 물질 및 이의 제조방법
CN110312529A (zh) 包含核心和结合至核心表面的唾液酸、唾液酸乳糖或其衍生物的缀合物及其用途
US12397064B2 (en) Virucidal nanoparticles and use thereof against influenza virus
Boyoglu et al. Enhanced delivery and expression of a nanoencapsulated DNA vaccine vector for respiratory syncytial virus
CN116367843A (zh) 病毒抑制剂
WO2022026622A2 (en) Treatment of viral diseases
US20130280204A1 (en) Polymer-Attached Inhibitors of Influenza Virus
WO2021236626A1 (en) Mucoretentive antiviral technologies
US20230256049A1 (en) Materials and methods for the prevention and treatment of viral respiratory diseases
US20140348777A1 (en) Polysorbitol-Based Osmotically Active Transporter and Gene Therapy Using Same
CN119156396A (zh) 用于治疗covid感染的方法和组合物
JP2023536119A5 (https=)
US20250352653A1 (en) Neuron targeted 2-deoxyglucose dendrimer for imaging and treatment of neurological diseases
US20240350511A1 (en) Treatment of covid-19
CN121401419A (zh) 针对vdac1靶点的物质在制备产品中的应用以及防治由rsv引起的疾病的药物
Alshammari et al. Rifampicin-Loaded Nanoparticles for Targeted Tuberculosis Therapy: Enhancing Delivery and Efficacy
WO2025224455A1 (en) Sulfonated particles
WO2026006276A9 (en) Materials and methods for the prevention and treatment of viral diseases
WO2025054715A1 (en) Covid-19 trap technology platform

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230630